Association Between Programmed Death-Ligand 1 Expression and the Vascular Endothelial Growth Factor Pathway in Angiosarcoma
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Association Between Programmed Death-Ligand 1 Expression and the Vascular Endothelial Growth Factor Pathway in Angiosarcoma
Authors
Keywords
-
Journal
Frontiers in Oncology
Volume 8, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2018-03-22
DOI
10.3389/fonc.2018.00071
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden
- (2017) Zachary R. Chalmers et al. Genome Medicine
- Prognostic implications of PD-L1 expression in patients with soft tissue sarcoma
- (2016) Chan Kim et al. BMC CANCER
- Genetic Ancestry and Natural Selection Drive Population Differences in Immune Responses to Pathogens
- (2016) Yohann Nédélec et al. CELL
- Genetic Adaptation and Neandertal Admixture Shaped the Immune System of Human Populations
- (2016) Hélène Quach et al. CELL
- Comprehensive profiling of metaplastic breast carcinomas reveals frequent overexpression of programmed death-ligand 1
- (2016) Upasana Joneja et al. JOURNAL OF CLINICAL PATHOLOGY
- Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy
- (2015) Suzanne L. Topalian et al. CANCER CELL
- Prevalence of tumor-infiltrating lymphocytes and PD-L1 expression in the soft tissue sarcoma microenvironment
- (2015) Sandra P. D’Angelo et al. HUMAN PATHOLOGY
- PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy
- (2015) S. P. Patel et al. MOLECULAR CANCER THERAPEUTICS
- PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
- (2015) Dung T. Le et al. NEW ENGLAND JOURNAL OF MEDICINE
- Programmed Cell Death 1 (PD-1) and Its Ligand (PD-L1) in Common Cancers and Their Correlation with Molecular Cancer Type
- (2014) Z. Gatalica et al. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
- Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti-PD-1 Therapy
- (2014) J. M. Taube et al. CLINICAL CANCER RESEARCH
- MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer
- (2014) Thomas Powles et al. NATURE
- Vascular Normalization as an Emerging Strategy to Enhance Cancer Immunotherapy
- (2013) Y. Huang et al. CANCER RESEARCH
- CD8+tumor-infiltrating lymphocytes at primary sites as a possible prognostic factor of cutaneous angiosarcoma
- (2013) Hiroko Fujii et al. INTERNATIONAL JOURNAL OF CANCER
- Tumor Infiltrating PD1-Positive Lymphocytes and the Expression of PD-L1 Predict Poor Prognosis of Soft Tissue Sarcomas
- (2013) Jung Ryul Kim et al. PLoS One
- Inverse Association between Programmed Death Ligand 1 and Genes in the VEGF Pathway in Primary Clear Cell Renal Cell Carcinoma
- (2013) R. W. Joseph et al. Cancer Immunology Research
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- (2012) Suzanne L. Topalian et al. NEW ENGLAND JOURNAL OF MEDICINE
- NanoStriDE: normalization and differential expression analysis of NanoString nCounter data
- (2011) Christopher D Brumbaugh et al. BMC BIOINFORMATICS
- The prognostic influence of tumour-infiltrating lymphocytes in cancer: a systematic review with meta-analysis
- (2011) M J M Gooden et al. BRITISH JOURNAL OF CANCER
- Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and Treg cells
- (2011) Andrea Facciabene et al. NATURE
- Hypoxia Potentiates Glioma-Mediated Immunosuppression
- (2011) Jun Wei et al. PLoS One
- Angiosarcoma
- (2010) Robin J Young et al. LANCET ONCOLOGY
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now